Clinical ResearchCoronary RevascularizationThe Negative Impact of Incomplete Angiographic Revascularization on Clinical Outcomes and Its Association With Total Occlusions: The SYNTAX (Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) Trial
Key Words
Abbreviations and Acronyms
Cited by (0)
The SYNTAX Trial was funded by Boston Scientific. Drs. Dawkins, Pereda, and Huang are all full-time employees in Boston Scientific. Dr. Dawkins holds stock in Boston Scientific. Dr. Mack has served on the Speakers' Bureau of Cordis and Medtronic and reports no financial disclosures. Dr. Feldman has received research grants and consulting fees from Abbott Vascular, Boston Scientific, and Edwards Lifesciences. Dr. Morice reported that her institution received a research grant from Boston Scientific. Dr. James has received institutional research grants from Medtronic, Inc., Vascular Solutions, Terumo, Inc., AstraZeneca, and Eli Lilly; and has served on the advisory board and received honoraria from AstraZeneca, Eli Lilly, Abbott Vascular, Boston Scientific, and Medtronic. Dr. Kappetein served as a member of the steering committee for the SYNTAX trial, sponsored by Boston Scientific. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.